4Williams DO, Holubkov R, Yeh W, et al. Percutaneous coronary intervention in the current era compared with 1985 -1986: the National Heart, Lung, and Blood Institute Registries. Circulation,2000, 102 : 29102-29141.
5Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med, 2003,349:1315-1323.
6Lemos PA, Saia F, Hofma SH, et al. Short- and long- term clinical benefit of sirolimus-eluting stnets compared to conventional bare stents for patients with acute myocardial infarction. J Am Coll Cardiol, 2004,43:704-708.
7McFadden EP, Stabile E, Regar E, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet, 2004, 364:1519-1521.
8Schampaert E, Cohen EA, SchluterM, et all The Canadian study of the sirolimus-eluting stent in the treatment of patients with long denovo lesions in small native coronary arteries ( C2SIR IUS). J Am Coll Cardio, 2004, 43: 1110-1115.
9Stone GW, Ellis SG, Cox DA, et all One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-Ⅳ trial. Circulation, 2004, 109: 1942-1947.
10vKastrati A, Schomig A, Elezi S, et al. Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol, 1997, 30 : 1428-1436.
